N-Ratio: a Novel Independent Prognostic Factor for Patients with Stage-III Cutaneous Melanoma

[1]  S. Mocellin,et al.  The Ratio Between Metastatic and Examined Lymph Nodes (N Ratio) Is an Independent Prognostic Factor in Gastric Cancer Regardless of the Type of Lymphadenectomy: Results From an Italian Multicentric Study in 1853 Patients , 2007, Annals of surgery.

[2]  B. Kuru.  Prognostic significance of total number of nodes removed, negative nodes removed, and ratio of positive nodes to removed nodes in node positive breast carcinoma. , 2006, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[3]  R. Cailliod,et al.  The prognostic impact of the extent of lymph node dissection in patients with stage III melanoma. , 2006, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[4]  W. Woodward,et al.  Prognostic value of nodal ratios in node-positive breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  D. McCready,et al.  Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma , 2006, Cancer.

[6]  Roy R. L. Bastien,et al.  Molecular classification of melanoma using real‐time quantitative reverse transcriptase‐polymerase chain reaction , 2005, Cancer.

[7]  Richard A Scolyer,et al.  Cutaneous melanoma , 2005, The Lancet.

[8]  Michael B Atkins,et al.  Management of cutaneous melanoma. , 2004, The New England journal of medicine.

[9]  Natale Cascinelli,et al.  An Evidence‐based Staging System for Cutaneous Melanoma 1 , 2004, CA: a cancer journal for clinicians.

[10]  E. Ross,et al.  The Metastatic/Examined Lymph Node Ratio is an Important Prognostic Factor after Pancreaticoduodenectomy for Pancreatic Adenocarcinoma , 2004, The American surgeon.

[11]  J. Manola,et al.  A Pooled Analysis of Eastern Cooperative Oncology Group and Intergroup Trials of Adjuvant High-Dose Interferon for Melanoma , 2004, Clinical Cancer Research.

[12]  M. Gore,et al.  Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials. , 2003, Cancer treatment reviews.

[13]  M. Lens,et al.  Interferon alfa therapy for malignant melanoma: a systematic review of randomized controlled trials. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Martin F. Mihm,et al.  Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  N Cascinelli,et al.  Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  N. Sampas,et al.  Molecular classification of cutaneous malignant melanoma by gene expression profiling , 2000, Nature.

[17]  D. Morton,et al.  Judging the therapeutic value of lymph node dissections for melanoma. , 2000, Journal of the American College of Surgeons.

[18]  Joseph P. Romano,et al.  Testing Statistical Hypotheses, Third Edition , 2008, Springer texts in statistics.

[19]  S. Mocellin,et al.  DNA array-based gene profiling: from surgical specimen to the molecular portrait of cancer. , 2005, Annals of surgery.

[20]  C. Belluco,et al.  Ratio Between Metastatic and Examined Lymph Nodes Is an Independent Prognostic Factor After D2 Resection for Gastric Cancer: Analysis of a Large European Monoinstitutional Experience , 2003, Annals of Surgical Oncology.